Cerebrolysin
Porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids that mimic the action of endogenous neurotrophic factors (BDNF, GDNF, CNTF, NGF). Peptide fragments cross the blood-brain barrier and activate PI3K/Akt and MAPK/ERK signaling cascades, promoting neuronal survival, dendritic branching, and synaptic plasticity. Approved in over 48 countries for stroke recovery, traumatic brain injury, and dementia. Not FDA-approved in the United States.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- alt
- ast
- creatinine
- egfr
- hs-crp
- pork-allergy
- status-epilepticus
- severe-renal-impairment
- PMID:23886841Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial — J Stroke Cerebrovasc Dis, 2011
- PMID:12460136Neurotrophic effects of Cerebrolysin: a pleiotropic approach — Int Psychogeriatr, 2002
- PMID:28622962Efficacy and safety of Cerebrolysin in acute brain injury: a meta-analysis of randomized controlled trials — CNS Neurol Disord Drug Targets, 2017
Cerebrolysin is the nootropic with the largest clinical evidence base that most Western practitioners have never heard of. Over 200 clinical studies. Approved in 48 countries. The mechanism is essentially delivering a cocktail of brain-derived neurotrophic peptides directly into circulation, bypassing the synthesis bottleneck. The fact that it is not FDA-approved says more about regulatory economics than about efficacy data. Injectable administration creates a barrier to casual use, which is arguably a feature. The 21-day IM protocol at 5-10mL/day is the standard non-clinical cognitive enhancement approach. Cycle once or twice per year.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See Cerebrolysin in a protocol matched to you